Date: 2017-06-19
Type of information: Nomination
Compound:
Company: Medivir (Sweden)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 19, 2017, Medivir appointed John Öhd as its new Chief Medical Officer. John Öhd has been Medivir’s Director, Clinical Research & Development since 2014, prior to which he was senior director of Experimental Medicine at Shire in Nyon, Switzerland. John has held various positions at AstraZeneca in Södertälje, Sweden, including group director for early development in cognitive and neurodegenerative disorders. He worked in cancer research initially at Lund University where he received a PhD in Experimental Pathology and subsequently at Karolinska Institute. John received his MD from Linköping University, and trained clinically at Karolinska University Hospital.
Financial terms:
Latest news:
Is general: Yes
